People and Patients

Society at large and patients in particular benefit from a global system that accelerates the development and accessibility of new medicines, therapeutics and devices to improve health, reduce disease and improve quality of life and productivity while:

  • Increasing transparency of biomedical R&D priorities and activities
  • Enhancing credibility of the “social contract” of obligations of the industry and governments to the public and to consumers
  • Facilitating responsiveness of the enterprise to social and health challenges, meeting more, demanding, and complex healthcare needs, better and quicker
  • Fulfilling social responsibility obligations to individuals, communities, and nation-states, including the most vulnerable , whether defined by disease condition or social condition